https://doi.org/10.48047/AFJBS.6.si2.2024.6132-6157

African Journal of Biological Sciences
Journal homepage: http://www.afjbs.com
Research Paper Open Access

Emerging Therapeutic Targets in Oncology: Harnessing Immunomodulation for Cancer Treatment

Astha Jaiswal[1], Sudhir Kumar[2], Prashant Kumar[3], Shaweta Sharma[4], Akhil Sharma[5], Akanksha Sharma[5], Devika Tripathi[6*]

[1]Shri Sai College of Pharmacy, Handia, Prayagraj

[2]Faculty of Pharmaceutical Sciences, DAV University, Jalandhar

[3]M J P Rohilkhand University Bareilly

[4]School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India

[5]R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165

[*6]PSIT- Pranveer Singh Institute of Technology (Pharmacy), Kanpur

Corresponding author details: Devika Tripathi: tripd990@gmail.com

Volume6issuesi22024
Received:15May2024
Accepted:10June2024
doi:10.48047/AFJBS.6.si2.2024.6132-6157

Abstract: Cancer treatment has significantly evolved with the advent of immunotherapy, offering new avenues for harnessing the body's immune system to combat malignancies. This review explores the emerging therapeutic targets in oncology, focusing on the potential of immunomodulation to revolutionize cancer treatment. Immunomodulatory therapies, including immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, adoptive cell transfer, and oncolytic virus therapy, have shown promising results in various malignancies. However, their efficacy is often limited by the tumor microenvironment and immune evasion mechanisms. This review delves into novel therapeutic targets, such as T-cell co-stimulatory and co-inhibitory molecules (LAG-3, TIM-3, TIGIT), cytokines and chemokines (IL-2, IL-7, IL-12, IL-15, IL-21, CXCL9, CXCL10), and metabolic checkpoints (IDO1, arginase, adenosine pathway). Modulating the tumor microenvironment, targeting tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) are also examined for their therapeutic potential. Combination therapies, which integrate multiple immunomodulatory strategies with conventional treatments, are highlighted for their enhanced efficacy. The review discusses predictive and prognostic biomarkers essential for personalized immunotherapy and addresses the challenges of immune-related adverse events (irAEs) and resistance to treatment. Future directions emphasize the need for innovative approaches and personalized strategies to overcome current limitations and improve patient outcomes. This comprehensive review aims to provide a detailed understanding of the current landscape and future prospects of immunomodulation in oncology, highlighting the potential to transform cancer therapy and improve survival rates.

Keywords: Cancer, immunomodulation, immune system, malignancy, oncology, CAR-T cell therapy, LAG-3, TIM-3, TIGIT, IL-2, IL-7, IL-12, IL-15, IL-21, CXCL9, CXCL10, IDO1, arginase, adenosine, targeting tumor-associated macrophages, myeloid-derived suppressor cells, regulatory T cells, immune-related adverse events

Introduction

Cancer immunotherapy represents a paradigm shift in oncology, utilizing the body's immune system to identify and eradicate cancer cells. Unlike traditional treatments like chemotherapy and radiation, which directly target tumor cells, immunotherapy empowers immune cells to recognize and destroy malignant cells more effectively. The concept of cancer immunotherapy dates back over a century but has gained substantial momentum in recent years with breakthroughs in understanding the immune system's interaction with cancer (Shekarian *et al.*, 2015).

Key modalities include immune checkpoint inhibitors, which block proteins that prevent T cells from attacking cancer cells, and chimeric antigen receptor (CAR) T-cell therapy, which genetically engineers a patient's T cells to target specific cancer antigens. Other strategies, such as cancer vaccines and oncolytic viruses, also play significant roles in the expanding arsenal of immunotherapies (Andrea *et al.*, 2022).

Immunomodulation, the strategic alteration of immune system activity, is at the heart of cancer immunotherapy. Its importance lies in the ability to enhance the immune system's capacity to fight cancer while minimizing collateral damage to healthy tissues. Tumors often develop mechanisms to evade immune detection, such as expressing proteins that inhibit T-cell activity or creating an immunosuppressive tumor microenvironment. Immunomodulatory therapies aim to counteract these evasion tactics, restoring the immune system's ability to target and eliminate cancer cells (Liu *et al.*, 2023).

For instance, immune checkpoint inhibitors like anti-PD-1/PD-L1 and anti-CTLA-4 antibodies release the brakes on T cells, enabling a more robust anti-tumor response. Additionally, modulating the tumor microenvironment by targeting regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) can shift the balance from immunosuppression to immune activation. This multifaceted approach is crucial for improving the efficacy of cancer treatment and achieving durable responses in patients (Song *et al.*, 2018).

This review article aims to provide a comprehensive exploration of the emerging therapeutic targets in oncology, with a particular focus on harnessing immunomodulation for cancer treatment.

Historical Perspective and Evolution of Immunomodulation

"Table 1" encapsulates key milestones in the historical development and evolution of immunomodulation in cancer treatment.

Table 1. Historical development and evolution of immunomodulation in cancer treatment.

Era	Milestone	Description
Late 19th Century	Coley's Toxins	Dr. William Coley used killed bacteria to stimulate the immune system, observing tumor regression in some cancer patients (Carlson *et al.*, 2020).
Mid-20th Century	Immune Surveillance Theory	Proposed the concept that the immune system can detect and eliminate emerging tumor cells, sparking interest in cancer immunology (Gilbert and Pirkmajer, 2023).
1970s - 1980s	Monoclonal Antibodies	Development of monoclonal antibodies targeting specific antigens on cancer cells, leading to treatments like Rituximab for B-cell malignancies (Tazi *et al.*, 2011).
1990s	Discovery of CTLA-4 and PD-1 Pathways	James P. Allison and Tasuku Honjo's work revealed how tumors evade immune detection through immune checkpoints (Wang *et al.*, 2017).
2011	Approval of Ipilimumab (anti-CTLA-4)	First checkpoint inhibitor approved for metastatic melanoma, marking a new era in cancer immunotherapy (Marquez-Rodas *et al.*, 2015).
2014 - 2015	Approval of PD-1 and PD-L1 Inhibitors	Pembrolizumab and Nivolumab approved, showing efficacy in various cancers by blocking PD-1/PD-L1 pathways (Jia *et al.*, 2018).
2017	Approval of CAR-T Cell Therapies (Kymriah and Yescarta)	Engineered T cells with chimeric antigen receptors targeting cancer cells, achieving success in refractory hematologic cancers (Leyfman, 2018).

Recent Years	Expansion of Immunomodulatory Strategies	Exploration of new immune checkpoints (LAG-3, TIM-3), modulation of the tumor microenvironment, oncolytic viruses, and cytokines/chemokines (Bayode *et al.*, 2024).
	Advances in Cytokines and Metabolic Pathways	Research into the role of cytokines, chemokines, and metabolic pathways in cancer immunity, opening new therapeutic avenues (Bhat *et al.*, 2021).

Major Immunomodulatory Therapies

Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a class of drugs that block proteins used by cancer cells to evade detection and destruction by the immune system. These proteins, known as checkpoints, normally help keep immune responses in check, preventing autoimmune reactions. However, cancer cells exploit these checkpoints to protect themselves from immune attack. By inhibiting these checkpoints, immune checkpoint inhibitors restore the immune system's ability to recognize and kill cancer cells (Lee *et al.*, 2016).

CTLA-4 Inhibitors

CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) is a protein receptor that acts as an immune checkpoint, downregulating immune responses. It is found on the surface of T cells and competes with the co-stimulatory molecule CD28 for binding to B7 molecules on antigen-presenting cells (APCs). When CTLA-4 binds to B7, it sends an inhibitory signal to T cells, reducing their activity. Ipilimumab is the most well-known CTLA-4 inhibitor. It was the first immune checkpoint inhibitor approved by the FDA in 2011 for the treatment of metastatic melanoma. By blocking CTLA-4, Ipilimumab enhances T-cell activation and proliferation, leading to a stronger anti-tumor response (Zhang *et al.*, 2016; Hargadon *et al.*, 2018). Mechanism of action of CTLA-4 inhibitors in cancer treatment are summarized in “figure 1”.



Figure 1. Mechanism of action of CTLA-4 inhibitors in cancer treatment

It is used in metastatic melanoma and as a combination therapy for various cancers, including renal cell carcinoma and colorectal cancer. It also have common side effects such as immune-related adverse events (irAEs) such as colitis, hepatitis, dermatitis and endocrinopathies (Rotte, 2019).

PD-1/PD-L1 Inhibitors

PD-1 (Programmed Cell Death Protein 1) is another checkpoint protein on the surface of T cells. It interacts with its ligands, PD-L1 and PD-L2, which can be expressed by cancer cells and other cells within the tumor microenvironment. The binding of PD-1 to PD-L1 or PD-L2 sends an inhibitory signal to T cells, leading to decreased T-cell activity and immune evasion by cancer cells (Mocan *et al.*, 2019).

PD-1 inhibitors includes pembrolizumab (keytruda), nivolumab (opdivo) and PD-L1 inhibitors includes atezolizumab (tecentriq), durvalumab (imfinzi), avelumab (bavencio) (Lee *et al.*, 2019). The mechanism of action of PD-1/PD-L1 inhibitors in cancer treatment are summarized in “figure 2”.



Figure 2. Mechanism of action of PD-1/PD-L1 inhibitors in cancer treatment

It is used in various cancers, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, head and neck squamous cell carcinoma and Hodgkin lymphoma. While it also has common side effects such as immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis, endocrinopathies and skin reactions (Prasad *et al.*, 2017).

Immune checkpoint inhibitors, including CTLA-4 inhibitors and PD-1/PD-L1 inhibitors, have revolutionized cancer therapy by harnessing the power of the immune system to fight cancer (Yu *et al.*, 2022). By blocking inhibitory signals that suppress immune responses, these drugs enhance T-cell activity, leading to improved anti-tumor responses in various malignancies. However, they are also associated with unique immune-related adverse events that require careful management (Butt and Mills, 2014).

CAR-T Cell Therapy

CAR-T cell therapy is a groundbreaking immunotherapy that involves genetically modifying a patient's T cells to target and kill cancer cells. This personalized treatment begins with the collection of T cells from the patient, which are then engineered in the laboratory to express chimeric antigen receptors (CARs) that recognize specific antigens on cancer cells. Once modified, these CAR-T cells are expanded to large numbers and infused back into the patient, where they seek out and destroy cancer cells (Abken, 2021).

CAR-T cell therapy has shown remarkable efficacy, particularly in treating hematologic malignancies such as B-cell acute lymphoblastic leukemia (ALL) and large B-cell lymphoma. Notable therapies include Tisagenlecleucel (Kymriah) and Axicabtagene Ciloleucel (Yescarta), both targeting the CD19 antigen. Despite its success, CAR-T cell therapy presents

challenges, including severe side effects like cytokine release syndrome (CRS) and neurotoxicity, as well as complexities in manufacturing (Ahmad *et al.*, 2020; Locke *et al.*, 2020).

Moreover, tumors may develop resistance by losing the target antigen, necessitating ongoing research and innovation. Efforts are underway to enhance CAR-T cell designs, explore combination therapies, and expand their use to solid tumors (Stern *et al.*, 2020).

Cancer Vaccines

Cancer vaccines represent a promising approach in oncology, designed to stimulate the immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases, cancer vaccines aim to treat existing cancers or prevent cancer recurrence by enhancing the body's immune response against tumor-specific or tumor-associated antigens. There are two main types of cancer vaccines: preventive (prophylactic) and therapeutic (treatment) vaccines (Taefehshokr *et al.*, 2020).

Preventive vaccines, like the human papillomavirus (HPV) vaccines (Gardasil and Cervarix) and the hepatitis B virus (HBV) vaccine, prevent cancers caused by infections. Therapeutic vaccines, such as Sipuleucel-T (Provenge) for metastatic prostate cancer, dendritic cell vaccines, peptide and protein vaccines, and whole tumor cell vaccines, aim to treat existing cancers by strengthening the immune response against cancer cells. These vaccines work by presenting tumor antigens to the immune system, prompting an immune response that targets cancer cells (Selvarajan *et al.*, 2012).

Despite their potential, cancer vaccines face challenges such as immune evasion by tumors, limited efficacy in some patients, and the complexity and cost of developing personalized vaccines. However, cancer vaccines offer several advantages, including target specificity, durable immune responses, and the potential for combination with other therapies. Future directions for cancer vaccines include the development of neoantigen vaccines, novel adjuvants and delivery systems, combination therapies, and the use of mRNA technology to improve their effectiveness (Katsikis *et al.*, 2024).

Adoptive Cell Transfer (ACT)

Adoptive Cell Transfer (ACT) is an innovative and personalized form of immunotherapy that involves extracting a patient’s immune cells, expanding or genetically modifying them in the laboratory to enhance their anti-tumor activity, and then reinfusing them back into the patient.

This approach aims to boost the patient's immune system to more effectively target and destroy cancer cells. ACT has shown promising results, particularly in treating certain types of cancers that are resistant to conventional therapies (Kirtane *et al.*, 2024).

Types of Adoptive Cell Transfer

Tumor-Infiltrating Lymphocytes (TILs)

This approach involves isolating T cells that have naturally infiltrated the tumor. These T cells are extracted from the tumor tissue, expanded to large numbers in the laboratory, and then reinfused into the patient. TIL therapy has been particularly effective in treating metastatic melanoma (Hall *et al.*, 2016).

Engineered T-cell Receptor (TCR) Therapy

T cells are genetically engineered to express T-cell receptors that specifically recognize cancer antigens presented by the patient's tumor cells. This enhances the T cells' ability to target and destroy cancer cells. TCR therapy is designed to target intracellular tumor antigens presented by MHC molecules, offering a broad range of potential targets (Ping *et al.*, 2018).

Chimeric Antigen Receptor (CAR) T-cell Therapy

CAR-T therapy involves engineering T cells to express chimeric antigen receptors that recognize specific antigens on the surface of cancer cells. This has shown remarkable success in treating certain blood cancers, such as B-cell acute lymphoblastic leukemia (ALL) and large B-cell lymphoma (Hong *et al.*, 2020).

Mechanism of Action

ACT works by boosting the patient's immune response to cancer. The process typically involves several steps which is summarized in "figure 3".



Figure 3. Mechanism of action of ACT in cancer treatment

Advantages and Challenges

ACT is tailored to the individual patient's immune cells, offering a highly personalized treatment approach. ACT has shown significant efficacy in certain cancers, achieving durable responses in cases where other treatments have failed. Engineered T cells can be designed to target specific cancer antigens, reducing damage to healthy cells (Bastien *et al.*, 2019).

The process of extracting, expanding, or modifying T cells is complex and expensive, limiting its widespread availability. ACT can cause severe side effects, such as cytokine release syndrome (CRS) and neurotoxicity, requiring careful management. Tumors can develop mechanisms to evade the immune response, such as losing the target antigen or creating an immunosuppressive microenvironment (Wolf *et al.*, 2019).

Oncolytic Virus Therapy

Oncolytic virus therapy is an innovative approach in cancer treatment that utilizes genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells while sparing normal cells. These viruses are designed to replicate within cancer cells, causing them to lyse (break down) and release viral progeny that can further infect neighboring cancer cells. Additionally, oncolytic viruses can stimulate anti-tumor immune responses by exposing tumor

antigens and enhancing immune cell infiltration into the tumor microenvironment (Rahman and Mc Fadden, 2021).

This dual mechanism of action makes oncolytic virus therapy a promising strategy for treating various types of cancers, including those that are resistant to conventional therapies. Current research focuses on enhancing the specificity and safety of oncolytic viruses, optimizing their delivery to tumors, and exploring combination therapies with other immunotherapies or standard treatments to improve overall efficacy. While challenges such as immune clearance of the virus and pre-existing immunity in patients exist, ongoing advancements in viral engineering and understanding of tumor biology hold significant potential for expanding the role of oncolytic virus therapy in clinical oncology (Chaurasiya *et al.*, 2020).

Emerging Therapeutic Targets

T-cell Co-stimulatory and Co-inhibitory Molecules

T-cell co-stimulatory and co-inhibitory molecules play crucial roles in regulating immune responses, influencing the activation, proliferation, and effector functions of T cells. These molecules serve as checkpoints that modulate the intensity and duration of immune responses to maintain immune homeostasis and prevent autoimmune reactions (Zhang and Vignali, 2016).

LAG-3

LAG-3 (Lymphocyte-activation gene 3) is a co-inhibitory receptor expressed on activated T cells, natural killer (NK) cells, and other immune cells. It binds to MHC class II molecules with higher affinity than CD4, thereby downregulating T-cell activation and proliferation. LAG-3 is implicated in immune suppression within the tumor microenvironment and is being targeted to enhance anti-tumor immunity in cancers resistant to other therapies (Anderson *et al.*, 2016).

TIM-3

TIM-3 (T-cell Immunoglobulin and Mucin-domain containing-3) is another co-inhibitory receptor expressed on T cells, NK cells, and other immune cells. It interacts with galectin-9 and other ligands to promote immune tolerance and exhaustion of effector T cells. TIM-3 blockade has shown promise in reversing T-cell exhaustion and enhancing anti-tumor immune responses, particularly in combination with other checkpoint inhibitors (Chen *et al.*, 2023).

TIGIT

TIGIT (T-cell Immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on T cells and NK cells that binds to CD155 (PVR) and CD112 (PVRL2) ligands on antigen-presenting cells and tumor cells. TIGIT signaling suppresses T-cell activation and cytokine production, promoting immune evasion by tumors. Targeting TIGIT aims to restore T-cell function and enhance immune surveillance against cancer cells, particularly in the context of immunotherapy resistance (Liu *et al.*, 2017).

These molecules represent critical targets in the field of cancer immunotherapy, where manipulating their interactions holds promise for overcoming immune suppression within the tumor microenvironment and improving responses to existing therapies (Zhao *et al.*, 2023).

Cytokines and Chemokines

Cytokines and chemokines are key signaling molecules that orchestrate immune responses by regulating the activation, proliferation, migration, and function of immune cells. Cancer immunotherapy, several cytokines and chemokines play crucial roles:

Interleukin-2 (IL-2)

IL-2 is a critical cytokine that stimulates the proliferation and differentiation of T cells, particularly cytotoxic T cells and regulatory T cells (Tregs). It has been used therapeutically to enhance immune responses in cancer immunotherapy, including in adoptive T-cell transfer therapies like CAR-T cell therapy (Lan *et al.*, 2008).

Interleukin-7 (IL-7)

IL-7 supports the survival and proliferation of naive and memory T cells by binding to its receptor, IL-7Rα. It plays a vital role in T-cell homeostasis and function, making it a potential target for enhancing immune responses in cancer therapies (Chen *et al.*, 2021).

Interleukin-12 (IL-12)

IL-12 is a potent inducer of Th1 immune responses and enhances the cytotoxic activity of NK cells and CD8+ T cells. It promotes the production of IFN-γ and TNF-α, contributing to anti-tumor immunity. IL-12 has been studied in cancer immunotherapy to stimulate immune responses against tumors (Mirlekar and Pylayeva, 2021).

Interleukin-15 (IL-15)

IL-15 shares structural and functional similarities with IL-2 and plays a critical role in the proliferation, survival, and activation of NK cells and memory CD8+ T cells. IL-15 has shown promise in enhancing the anti-tumor activity of NK cells and T cells in preclinical and clinical studies (Guo *et al.*, 2017).

Interleukin-21 (IL-21)

IL-21 is a pleiotropic cytokine produced by activated CD4+ T cells and NK cells. It enhances the proliferation and effector functions of CD8+ T cells and NK cells and promotes antibody production by B cells. IL-21 has been investigated for its potential to enhance anti-tumor immune responses in various cancers (Davis *et al.*, 2007).

CXCL9 (MIG) and CXCL10 (IP-10)

CXCL9 and CXCL10 are chemokines induced by IFN-γ and play critical roles in recruiting effector T cells, particularly CD4+ and CD8+ T cells, to sites of inflammation or tumors. Their expression correlates with increased immune cell infiltration into tumors and has implications for cancer immunotherapy strategies aiming to enhance T-cell recruitment and activation.

These cytokines and chemokines represent integral components of the immune system's response to cancer, offering potential targets for therapeutic interventions aimed at enhancing anti-tumor immunity and improving outcomes in cancer patients (Tokunaga *et al.*, 2018).

Tumor Microenvironment Modulation

The tumor microenvironment (TME) plays a critical role in cancer progression and immune evasion, consisting of diverse cell types, cytokines, and extracellular matrix components that support tumor growth and metastasis. Modulating the TME is a promising strategy in cancer therapy, aiming to enhance anti-tumor immune responses and improve treatment outcomes (Neophytou *et al.*, 2021).

Targeting Tumor-associated Macrophages (TAMs)

TAMs are a major component of the TME with diverse functions ranging from promoting tumor growth, angiogenesis, and metastasis to suppressing anti-tumor immunity. Targeting TAMs aims to reprogram them from a pro-tumorigenic M2-like phenotype to an anti-tumor M1-like phenotype, thereby enhancing immune surveillance and promoting tumor regression (Basak *et al.*, 2023).

Myeloid-Derived Suppressor Cells (MDSCs)

MDSCs are a heterogeneous population of immature myeloid cells that suppress anti-tumor immune responses and promote tumor progression. MDSCs inhibit T-cell activation and promote Treg expansion within the TME. Targeting MDSCs aims to reduce their immunosuppressive effects and enhance anti-tumor immunity (Gao *et al.*, 2021).

Regulatory T Cells (Tregs)

Tregs are a subset of CD4+ T cells that play a crucial role in maintaining immune tolerance and suppressing excessive immune responses. In the TME, Tregs inhibit anti-tumor immune responses and promote immune evasion by suppressing effector T cells. Targeting Tregs aims to reduce their suppressive function and restore effective anti-tumor immunity.

Understanding the complex interactions within the TME and developing strategies to effectively modulate its immunosuppressive components are critical for advancing cancer immunotherapy (Chen *et al.*, 2016).

Metabolic Checkpoints

Metabolic checkpoints in cancer immunotherapy refer to critical enzymes and pathways within the tumor microenvironment (TME) that regulate immune responses and tumor progression by altering metabolic processes. Targeting these checkpoints represents a novel approach to enhancing anti-tumor immunity (Xu *et al.*, 2021).

IDO1

IDO1 (Indoleamine 2,3-dioxygenase 1) is an enzyme involved in the catabolism of tryptophan, an essential amino acid for T-cell proliferation and function. Increased IDO1 expression in tumors leads to tryptophan depletion and the accumulation of immunosuppressive metabolites such as kynurenine, creating an immune-tolerant TME. Inhibiting IDO1 aims to restore T-cell function and enhance anti-tumor immune responses (Mbongue *et al.*, 2015).

Arginase

Arginase enzymes, particularly arginase 1 (ARG1), compete with nitric oxide synthase (NOS) for the substrate L-arginine, thereby depleting L-arginine levels in the TME. L-arginine depletion impairs T-cell proliferation and function, contributing to immune suppression and tumor immune evasion. Targeting arginase aims to restore L-arginine availability and enhance T-cell-mediated anti-tumor responses (Chioda *et al.*, 2013).

Adenosine Pathway

Adenosine is a purine nucleoside that accumulates in the TME due to increased ATP breakdown by tumor cells and immune cells under hypoxic conditions. Adenosine binds to adenosine receptors (A2AR) on immune cells, particularly T cells, leading to immune suppression and T-cell exhaustion. Inhibiting adenosine receptors or enzymes involved in adenosine production (such as CD73) aims to block immunosuppressive signals and enhance anti-tumor immune responses (Feng *et al.*, 2020).

Combination Therapies

Rationale for Combination Approaches

Combination approaches in cancer therapy are grounded in the rationale that targeting multiple pathways or mechanisms simultaneously can enhance treatment efficacy, overcome resistance mechanisms, and improve overall patient outcomes.

Synergistic Effects

Different therapeutic agents or modalities may act synergistically, meaning their combined effect is greater than the sum of their individual effects. For example, combining chemotherapy with targeted therapies or immunotherapies can enhance cancer cell killing while minimizing toxicity to normal tissues (Zhang *et al.*, 2016).

Complementary Mechanisms of Action

Combining therapies that target different aspects of cancer biology or the tumor microenvironment (TME) can effectively disrupt multiple pathways critical for cancer growth and survival. For instance, combining a therapy targeting a specific oncogenic mutation with an immunotherapy that enhances anti-tumor immune responses can provide a comprehensive attack on cancer cells (Marshall and Djamgoz, 2018).

Overcoming Resistance

Cancer cells often develop resistance to single-agent therapies through various mechanisms, such as mutations, alternative signaling pathways, or immune evasion strategies. Combination therapies can mitigate resistance by targeting multiple vulnerabilities or pathways that cancer cells may exploit for survival (Sharma and Allison, 2015).

Broadening Therapeutic Window

Some therapies may have dose-limiting toxicities when used alone. Combining therapies with different toxicity profiles can potentially widen the therapeutic window, allowing for higher doses or more prolonged treatment schedules without compromising patient safety (Ott *et al.*, 2017).

Optimizing Immunotherapy

Immunotherapy, such as immune checkpoint inhibitors or adoptive cell therapies, often benefits from combination with other modalities that enhance immune activation or reduce immunosuppressive signals within the TME. This approach aims to potentiate immune responses and improve response rates in patients who may not respond to immunotherapy alone (Zhu *et al.*, 2021).

Personalized Medicine

Combination therapies can be tailored based on individual tumor characteristics, biomarkers, or genetic profiles, allowing for a more personalized and targeted approach to treatment. This precision medicine approach increases the likelihood of therapeutic success while minimizing unnecessary treatments (Sicklick *et al.*, 2019).

The rationale for combination approaches in cancer therapy lies in their potential to achieve deeper and more sustained responses, reduce the likelihood of treatment resistance, and ultimately improve patient survival and quality of life (Block *et al.*, 2015).

Examples of Combination Strategies

Combination strategies in cancer therapy leverage the synergistic potential of different treatment modalities to enhance anti-tumor efficacy and improve patient outcomes.

Immune Checkpoint Inhibitors with Chemotherapy/Radiotherapy

Chemotherapy and radiotherapy can induce immunogenic cell death, releasing tumor antigens and promoting immune activation. Immune checkpoint inhibitors (ICIs) enhance this immune response by blocking inhibitory pathways, such as PD-1/PD-L1 or CTLA-4, thereby augmenting T-cell-mediated cytotoxicity against cancer cells. The combination of pembrolizumab (anti-PD-1 antibody) with chemotherapy (e.g., pembrolizumab + platinum-based chemotherapy for non-small cell lung cancer) or radiotherapy (e.g., pembrolizumab + radiation therapy for head and neck cancer) has shown improved response rates and prolonged

survival compared to chemotherapy or radiotherapy alone (Zhang *et al.*, 2021; Alexander *et al.*, 2020).

Dual Immune Checkpoint Blockade

Tumors may exploit multiple immune checkpoint pathways to evade immune surveillance. Dual blockade of complementary checkpoints can synergistically enhance T-cell activation and effector functions, overcoming resistance mechanisms. Combining nivolumab (anti-PD-1 antibody) with ipilimumab (anti-CTLA-4 antibody) has demonstrated superior outcomes in melanoma and renal cell carcinoma compared to monotherapy, with increased response rates and durable responses (Nikoo *et al.*, 2023).

Combining CAR-T with Immune Checkpoint Inhibitors

CAR-T cell therapy enhances T-cell specificity and cytotoxicity against cancer cells expressing target antigens. However, tumors may upregulate immune checkpoints like PD-L1 to evade CAR-T cell attack. Combining CAR-T cell therapy with ICIs can prevent T-cell exhaustion and enhance CAR-T cell persistence and function. Trials combining CAR-T cell therapies (e.g., CD19-targeted CAR-T cells for B-cell malignancies) with PD-1/PD-L1 inhibitors (e.g., pembrolizumab or nivolumab) aim to improve response rates and durability of responses in patients who have relapsed after CAR-T cell therapy (Hosseinkhani *et al.*, 2020).

These examples illustrate how combining different therapeutic approaches such as immune checkpoint inhibitors with chemotherapy/radiotherapy, dual immune checkpoint blockade, or CAR-T cell therapy with ICIs can capitalize on complementary mechanisms to achieve more potent anti-tumor effects, overcome resistance mechanisms, and improve outcomes for cancer patients (Jahangiri and Yu, 2024).

Biomarkers for Immunotherapy

Biomarkers play crucial roles in guiding the selection of patients for immunotherapy, predicting treatment response, and monitoring therapeutic efficacy. They can be broadly categorized into predictive biomarkers, prognostic biomarkers, and biomarkers that guide therapy decisions.

Predictive Biomarkers

Predictive biomarkers in cancer immunotherapy are crucial indicators that help predict which patients are likely to respond favorably to specific treatments, particularly immune checkpoint

inhibitors and other immunotherapies. These biomarkers enable clinicians to personalize treatment decisions by identifying patients who have a higher probability of benefiting from therapy while minimizing unnecessary treatments and potential side effects in non-responders. Key predictive biomarkers include PD-L1 expression on tumor or immune cells, which correlates with improved responses to PD-1/PD-L1 inhibitors in various cancers like non-small cell lung cancer (NSCLC) and melanoma (Jafarzadeh *et al.*, 2021).

Additionally, microsatellite instability (MSI) or mismatch repair (MMR) deficiency status indicates heightened sensitivity to immune checkpoint blockade, such as pembrolizumab and nivolumab, across different cancer types. Tumor mutational burden (TMB), measuring the number of mutations per tumor genome, also serves as a predictive biomarker, associated with enhanced neoantigen formation and better response to immunotherapy. These biomarkers underscore the shift towards personalized medicine in oncology, guiding treatment strategies that maximize therapeutic benefit based on individual tumor biology and immune profiles (Andre *et al.*, 2021; Chan *et al.*, 2019)

Prognostic Biomarkers

Prognostic biomarkers in cancer immunotherapy provide valuable insights into disease prognosis and patient outcomes independent of treatment. These biomarkers help clinicians stratify patients based on their likelihood of disease progression, overall survival, and response to therapy. Key prognostic biomarkers include tumor stage and histological characteristics, which provide critical information about disease severity and aggressiveness (Gnjatic *et al.*, 2017).

Additionally, the presence of tumor infiltrating lymphocytes (TILs) within the tumor microenvironment serves as a prognostic indicator, with higher levels associated with improved prognosis and better response to immunotherapy across various cancer types. These biomarkers play a pivotal role in clinical decision-making, aiding in the selection of appropriate treatment strategies and the management of patient care. By incorporating prognostic biomarkers into clinical practice, healthcare providers can better predict disease outcomes and tailor interventions to optimize patient outcomes in cancer immunotherapy (Fanale *et al.*, 2022).

Biomarker-guided Therapy

Biomarker-guided therapy represents a cornerstone of precision medicine in oncology, revolutionizing treatment approaches by leveraging specific molecular and genetic characteristics of tumors to tailor therapies to individual patients. This approach utilizes biomarkers such as genetic mutations, protein expression levels (e.g., PD-L1), microsatellite instability (MSI), or tumor mutational burden (TMB) to guide treatment decisions. For instance, companion diagnostics for PD-L1 expression are used to select patients likely to respond to immune checkpoint inhibitors targeting PD-1/PD-L1 pathways (Cortiana *et al.*, 2024).

Similarly, genomic profiling through techniques like next-generation sequencing (NGS) identifies actionable mutations that inform the use of targeted therapies or immunotherapies. Biomarker-guided therapy not only enhances treatment efficacy by matching patients with therapies most likely to benefit them but also minimizes exposure to ineffective treatments, thereby optimizing patient outcomes and reducing unnecessary side effects. As research continues to uncover new biomarkers and refine existing ones, biomarker-guided therapy holds promise for advancing personalized cancer care, improving response rates, and ultimately transforming the landscape of cancer treatment (Pankiw *et al.*, 2023).

Challenges and Future Directions

In the realm of cancer immunotherapy, significant strides have been made, yet several challenges and avenues for future advancements persist. One major hurdle is overcoming resistance mechanisms that emerge following initial positive responses to immunotherapy. Factors contributing to resistance include tumor heterogeneity, adaptive immune resistance, and the activation of alternative immune checkpoints like TIM-3 and LAG-3. To address this, researchers are exploring combination therapies targeting multiple checkpoints concurrently, employing biomarker-driven strategies to detect resistance early, and developing novel immunotherapeutic agents that enhance T-cell functionality or modify the tumor microenvironment (Dai *et al.*, 2019).

Another critical challenge lies in managing immune-related adverse events (irAEs) induced by immune checkpoint inhibitors, which can affect various organs and range from mild to severe. Balancing effective anti-tumor responses with the management of irAEs requires a nuanced approach. Advances in understanding the underlying mechanisms of irAEs, early detection using biomarkers, and the refinement of immunosuppressive treatment protocols are essential to improve patient safety and treatment outcomes (Disis *et al.*, 2023).

The concept of personalized immunotherapy is also gaining traction, focusing on identifying predictive biomarkers and tumor-specific characteristics to tailor treatments to individual patients. This approach aims to maximize treatment efficacy while minimizing adverse effects. Integrating genomic profiling, immune profiling, and advanced imaging technologies holds promise for refining patient stratification, optimizing treatment selection, and dynamically monitoring treatment responses (Batis *et al.*, 2021).

Furthermore, the landscape of immunomodulation is evolving with the advent of novel technologies such as oncolytic viruses, RNA-based therapies like mRNA vaccines, and engineered immune cells such as CAR-T and TCR-T cells. These innovations aim to enhance immune activation, target specific tumor antigens more effectively, and circumvent immunosuppressive mechanisms within the tumor microenvironment. By addressing these challenges and leveraging emerging technologies, the field of immunotherapy strives to achieve durable responses and improve quality of life for cancer patients through continued innovation, clinical research, and interdisciplinary collaboration (Adhikary *et al.*, 2024).

Conclusion

Harnessing immunomodulation for cancer treatment represents a transformative frontier in oncology, marked by promising advancements and ongoing challenges. The identification of immune checkpoints, such as PD-1/PD-L1 and CTLA-4, has revolutionized therapeutic strategies, leading to unprecedented responses in certain cancers. However, the evolution of resistance mechanisms and the incidence of immune-related adverse events underscore the complexity of immunotherapy. Looking forward, personalized approaches that integrate predictive biomarkers and genomic profiling hold immense potential to refine patient selection and optimize treatment outcomes. Emerging technologies like CAR-T cell therapy, oncolytic viruses, and RNA-based therapies offer new avenues to augment immune responses and overcome tumor-induced immunosuppression. These innovations not only enhance the precision and efficacy of immunomodulatory treatments but also pave the way for combinatorial approaches that target multiple pathways simultaneously. Continued research efforts are crucial to unraveling the intricate interplay between tumors and the immune system, identifying novel therapeutic targets, and improving patient stratification. By harnessing the power of immunomodulation and embracing innovative technologies, the field is poised to usher in a new era of cancer therapy characterized by tailored treatments, durable responses, and improved quality of life for patients battling this complex disease.

Acknowledgement

Authors are highly thankful to their Universities/Colleges to provide library facilities for the literature survey.

References

1. Abken, H. (2021). Building on synthetic immunology and T cell engineering: a brief journey through the history of chimeric antigen receptors. *Human Gene Therapy*, *32*(19-20), 1011-1028.
2. Adhikary, S., Pathak, S., Palani, V., Acar, A., Banerjee, A., Al-Dewik, N. I., ... & Qoronfleh, M. W. (2024). Current Technologies and Future Perspectives in Immunotherapy towards a Clinical Oncology Approach. *Biomedicines*, *12*(1), 217.
3. Ahmad, A., Uddin, S., & Steinhoff, M. (2020). CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. International journal of molecular sciences, 21(11), 3906.
4. Alexander, M., Ko, B., Lambert, R., Gadgeel, S., & Halmos, B. (2020). The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. *Expert Review of Respiratory Medicine*, *14*(2), 137-147.
5. Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016). Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. *Immunity*, *44*(5), 989-1004.
6. André, T., Cohen, R., & Salem, M. E. (2022). Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022. *American Society of Clinical Oncology Educational Book*, *42*, 233-241.
7. Andrea, A. E., Chiron, A., Mallah, S., Bessoles, S., Sarrabayrouse, G., & Hacein-Bey-Abina, S. (2022). Advances in CAR-T cell genetic engineering strategies to overcome hurdles in solid tumors treatment. Frontiers in Immunology, 13, 830292.
8. Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., ... & Sa, G. (2023). Tumor-associated macrophages: An effective player of the tumor microenvironment. *Frontiers in Immunology*, *14*, 1295257.
9. Bastien, J. P., Minguy, A., Dave, V., & Roy, D. C. (2019, April). Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. In *Seminars in Immunology* (Vol. 42, p. 101306). Academic Press.

10. Batis, N., Brooks, J. M., Payne, K., Sharma, N., Nankivell, P., & Mehanna, H. (2021). Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. *Advanced Drug Delivery Reviews*, *176*, 113854.
11. Bayode, M. T., Babatunde, O. J., Chukwuemeka, P. O., Ogbonna, H. N., Nwokafor, C. V., Alonge, S. A., ... & Oshokoya, A. H. (2024). Modulating the immunosuppressive tumor microenvironment: Multi-synergistic cancer therapeutic approach with oncolytic viruses. World Journal of Advanced Research and Reviews, 21(1), 543-559.
12. Bhat, A. A., Nisar, S., Maacha, S., Carneiro-Lobo, T. C., Akhtar, S., Siveen, K. S., ... & Haris, M. (2021). Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Molecular cancer, 20, 1-20.
13. Block, K. I., Gyllenhaal, C., Lowe, L., Amedei, A., Amin, A. R., Amin, A., ... & Sidransky, D. (2015, December). Designing a broad-spectrum integrative approach for cancer prevention and treatment. In *Seminars in cancer biology* (Vol. 35, pp. S276-S304). Academic Press.
14. Butt, A. Q., & Mills, K. H. G. (2014). Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. *Oncogene*, *33*(38), 4623-4631.
15. Carlson, R. D., Flickinger Jr, J. C., & Snook, A. E. (2020). Talkin'toxins: from Coley's to modern cancer immunotherapy. Toxins, 12(4), 241.
16. Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019). Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Annals of Oncology*, *30*(1), 44-56.
17. Chaurasiya, S., Fong, Y., & Warner, S. G. (2020). Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges. *Cancers*, *12*(6), 1699.
18. Chen, D., Tang, T. X., Deng, H., Yang, X. P., & Tang, Z. H. (2021). Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis. *Frontiers in immunology*, *12*, 747324.
19. Chen, H., Zha, J., Tang, R., & Chen, G. (2023). T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases. *International Immunopharmacology*, *121*, 110418.
20. Chen, X., Du, Y., Lin, X., Qian, Y., Zhou, T., & Huang, Z. (2016). CD4+ CD25+ regulatory T cells in tumor immunity. International immunopharmacology, 34, 244-249.

21. Chioda, M., Marigo, I., Mandruzzato, S., Mocellin, S., & Bronte, V. (2013). Arginase, nitric oxide synthase, and novel inhibitors of L-arginine metabolism in immune modulation. In *Cancer Immunotherapy* (pp. 597-634). Academic Press.
22. Cortiana, V., Abbas, R. H., Chorya, H., Gambill, J., Mahendru, D., Park, C. H., & Leyfman, Y. (2024). Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian. *Cancers*, *16*(13), 2329.
23. Dai Phung, C., Nguyen, H. T., Tran, T. H., Choi, H. G., Yong, C. S., & Kim, J. O. (2019). Rational combination immunotherapeutic approaches for effective cancer treatment. *Journal of controlled release*, *294*, 114-130.
24. Davis, I. D., Skak, K., Smyth, M. J., Kristjansen, P. E., Miller, D. M., & Sivakumar, P. V. (2007). Interleukin-21 signaling: functions in cancer and autoimmunity. *Clinical Cancer Research*, *13*(23), 6926-6932.
25. Disis, M. L., Adams, S. F., Bajpai, J., Butler, M. O., Curiel, T., Dodt, S. A., ... & Odunsi, K. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. *Journal for immunotherapy of cancer*, *11*(6).
26. Fanale, D., Dimino, A., Pedone, E., Brando, C., Corsini, L. R., Filorizzo, C., ... & Bazan, V. (2022). Prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) in ovarian cancer. *Cancers*, *14*(18), 4344.
27. Feng, L. L., Cai, Y. Q., Zhu, M. C., Xing, L. J., & Wang, X. (2020). The yin and yang functions of extracellular ATP and adenosine in tumor immunity. *Cancer cell international*, *20*, 1-11.
28. Gao, X., Sui, H., Zhao, S., Gao, X., Su, Y., & Qu, P. (2021). Immunotherapy targeting myeloid-derived suppressor cells (MDSCs) in tumor microenvironment. *Frontiers in immunology*, *11*, 585214.
29. Gilbert, M., & Pirkmajer, S. (2023). Concepts in Biology: A Historical Perspective.
30. Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., ... & Butterfield, L. H. (2017). Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. *Journal for immunotherapy of cancer*, *5*, 1-18.
31. Guo, Y., Luan, L., Patil, N. K., & Sherwood, E. R. (2017). Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. *Cytokine & growth factor reviews*, *38*, 10-21.

32. Hall, M., Liu, H., Malafa, M., Centeno, B., Hodul, P. J., Pimiento, J., ... & Sarnaik, A. A. (2016). Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. *Journal for immunotherapy of cancer*, *4*, 1-12.
33. Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018). Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. *International immunopharmacology*, *62*, 29-39.
34. Hong, M., Clubb, J. D., & Chen, Y. Y. (2020). Engineering CAR-T cells for next-generation cancer therapy. *Cancer cell*, *38*(4), 473-488.
35. Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Abdoli Shadbad, M., Hajiasgharzadeh, K., Baghbanzadeh, A., ... & Baradaran, B. (2020). Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?. *International Journal of Molecular Sciences*, *21*(21), 8305.
36. Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2021). Biomarkers for predicting the outcome of various cancer immunotherapies. *Critical reviews in oncology/hematology*, *157*, 103161.
37. Jahangiri, S., & Yu, F. (2024). Fundamentals and Applications of Focused Ultrasound-Assisted Cancer Immune Checkpoint Inhibition for Solid Tumors. *Pharmaceutics*, *16*(3), 411.
38. Jia, L., Zhang, Q., & Zhang, R. (2018). PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. *Cancer biology & medicine*, *15*(2), 116.
39. Katsikis, P. D., Ishii, K. J., & Schliehe, C. (2024). Challenges in developing personalized neoantigen cancer vaccines. *Nature Reviews Immunology*, *24*(3), 213-227.
40. Kirtane, K., Elmariah, H., Chung, C. H., & Abate-Daga, D. (2021). Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. *Journal for immunotherapy of cancer*, *9*(7).
41. Lan, R. Y., Selmi, C., & Gershwin, M. E. (2008). The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). *Journal of autoimmunity*, *31*(1), 7-12.
42. Lee, H. T., Lee, S. H., & Heo, Y. S. (2019). Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology. Molecules, 24(6), 1190.
43. Lee, L., Gupta, M., & Sahasranaman, S. (2016). Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. The journal of clinical pharmacology, 56(2), 157-169.

44. Leyfman, Y. (2018). Chimeric antigen receptors: unleashing a new age of anti-cancer therapy. Cancer cell international, 18, 1-6.
45. Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023). Tumor vaccines: Unleashing the power of the immune system to fight cancer. Pharmaceuticals, 16(10), 1384.
46. Liu, X. G., Hou, M., & Liu, Y. (2017). TIGIT, a novel therapeutic target for tumor immunotherapy. *Immunological investigations*, *46*(2), 172-182.
47. Locke, F. L., Go, W. Y., & Neelapu, S. S. (2020). Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. *JAMA oncology*, *6*(2), 281-290.
48. Marquez-Rodas, I., Cerezuela, P., Soria, A., Berrocal, A., Riso, A., Gonzalez-Cao, M., & Martin-Algarra, S. (2015). Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of translational medicine, 3(18).
49. Marshall, H. T., & Djamgoz, M. B. (2018). Immuno-oncology: emerging targets and combination therapies. *Frontiers in oncology*, *8*, 315.
50. Mbongue, J. C., Nicholas, D. A., Torrez, T. W., Kim, N. S., Firek, A. F., & Langridge, W. H. (2015). The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity. *Vaccines*, *3*(3), 703-729.
51. Mirlekar, B., & Pylayeva-Gupta, Y. (2021). IL-12 family cytokines in cancer and immunotherapy. *Cancers*, *13*(2), 167.
52. Mocan, T., Sparchez, Z., Craciun, R., Bora, C. N., & Leucuta, D. C. (2019). Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. *Clinical and Translational Oncology*, *21*(6), 702-712.
53. Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021). The role of tumor microenvironment in cancer metastasis: Molecular mechanisms and therapeutic opportunities. *Cancers*, *13*(9), 2053.
54. Nikoo, M., Rabiee, F., Mohebbi, H., Eghbalifard, N., Rajabi, H., Yazdani, Y., ... & Akhavan-Sigari, R. (2023). Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. *International Immunopharmacology*, *117*, 109881.
55. Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M., & Wolchok, J. D. (2017). Combination immunotherapy: a road map. *Journal for immunotherapy of cancer*, *5*, 1-15.

56. Pankiw, M., Brezden-Masley, C., & Charames, G. S. (2023). Comprehensive genomic profiling for oncological advancements by precision medicine. *Medical Oncology*, *41*(1), 1.
57. Ping, Y., Liu, C., & Zhang, Y. (2018). T-cell receptor-engineered T cells for cancer treatment: current status and future directions. *Protein & cell*, *9*(3), 254-266.
58. Prasad, V., & Kaestner, V. (2017, April). Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. In *Seminars in oncology* (Vol. 44, No. 2, pp. 132-135). WB Saunders.
59. Rahman, M. M., & McFadden, G. (2021). Oncolytic viruses: newest frontier for cancer immunotherapy. *Cancers*, *13*(21), 5452.
60. Rotte, A. (2019). Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental & Clinical Cancer Research, 38(1), 255.
61. Selvarajan, S., George, M., & Dkhar, S. A. (2012). Recent Advances in Cancer Vaccines-An Update. *Journal of Cancer Research Updates*, *1*(2), 173-180.
62. Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. *Cell*, *161*(2), 205-214.
63. Shekarian, T., Valsesia-Wittmann, S., Caux, C., & Marabelle, A. (2015). Paradigm shift in oncology: targeting the immune system rather than cancer cells. *Mutagenesis*, *30*(2), 205-211.
64. Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., ... & Kurzrock, R. (2019). Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. *Nature medicine*, *25*(5), 744-750.
65. Song, M., Chen, X., Wang, L., & Zhang, Y. (2018). Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research, 30(2), 157.
66. Stern, L. A., Jonsson, V. D., & Priceman, S. J. (2020). CAR T cell therapy progress and challenges for solid tumors. *Tumor Microenvironment*, 297-326.
67. Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2020). Promising approaches in cancer immunotherapy. *Immunobiology*, *225*(2), 151875.
68. Tazi, I., Nafil, H., & Mahmal, L. (2011). Monoclonal antibodies in hematological malignancies: past, present and future. Journal of cancer research and therapeutics, 7(4), 399-407.

69. Tokunaga, R., Zhang, W. U., Naseem, M., Puccini, A., Berger, M. D., Soni, S., ... & Lenz, H. J. (2018). CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation–a target for novel cancer therapy. *Cancer treatment reviews*, *63*, 40-47.
70. Wang, J., Yuan, R., Song, W., Sun, J., Liu, D., & Li, Z. (2017). PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective. Journal of hematology & oncology, 10, 1-8.
71. Wolf, B., Zimmermann, S., Arber, C., Irving, M., Trueb, L., & Coukos, G. (2019). Safety and tolerability of adoptive cell therapy in cancer. *Drug safety*, *42*, 315-334.
72. Xu, Y., He, L., Fu, Q., & Hu, J. (2021). Metabolic reprogramming in the tumor microenvironment with immunocytes and immune checkpoints. *Frontiers in oncology*, *11*, 759015.
73. Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022). Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. *Frontiers in immunology*, *13*, 982026.
74. Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., ... & Cheng, Q. (2021). Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research, 40(1), 184.
75. Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., ... & Cheng, Q. (2021). Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. *Journal of Experimental & Clinical Cancer Research*, *40*(1), 184.
76. Zhang, Q., & Vignali, D. A. (2016). Co-stimulatory and co-inhibitory pathways in autoimmunity. *Immunity*, *44*(5), 1034-1051.
77. Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016). Nanomedicine of synergistic drug combinations for cancer therapy–Strategies and perspectives. *Journal of Controlled Release*, *240*, 489-503.
78. Zhao, J., Li, L., Yin, H., Feng, X., & Lu, Q. (2023). TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer. *International immunopharmacology*, *120*, 110358.
79. Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., ... & Pan, C. X. (2021). Combination strategies to maximize the benefits of cancer immunotherapy. *Journal of hematology & oncology*, *14*(1), 156.